IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst

2025-09-08 16:30:23 ET

The last time I wrote about IDEAYA Biosciences ( IDYA ), it was with respect to a Seeking Alpha article entitled " Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 ." With respect to this article, I noted that the company's opportunity to evaluate the use of this antibody-drug conjugate [ADC] IDE849 [SHR-4849] for the treatment of patients with advanced solid tumors. As an update on this front, the company and its partner Hengrui Pharma presented positive data from a phase 1 study targeting patients with small-cell lung cancer [SCLC] and also neuroendocrine carcinomas. When targeting 2nd-line patients with 2.4 mg/kg of IDE849, the objective response rate [ORR] was said to be 80%. However, when including the final data for patients of all lines of therapy, this number dropped a bit to 73.7%....

Read the full article on Seeking Alpha

For further details see: